세계의 인플루엔자 백신 시장 : 가수별, 백신 유형별, 기술별, 연령층별, 투여 경로별, 유통 채널별, 지역별 분석, 규모, 동향, 예측(-2030년)

The influenza vaccine, often referred to as the flu vaccine, is a critical tool in the field of preventive medicine aimed at reducing the spread and impact of influenza, a contagious respiratory illness caused by influenza viruses. One of the reasons leading to the rising demand for influenza vaccine in recent years is the increased awareness of the importance of vaccination in preventing contagious respiratory illnesses, especially in the wake of global pandemic like COVID-19, which has highlighted the significance of vaccination in public health. Seasonal influenza (flu) can lead to high hospitalization and mortality rates in high-risk populations, which results in significant healthcare burden globally. Thus, representing a need and large market opportunity for the influenza vaccine market. The global influenza vaccine market in 2024 stood at US8.96 billion, and is likely to reach US$13.32 billion by 2030.

Globally, influenza infections lead to 3-5 million severe cases and 290- 650 thousand deaths annually. Some of the factors driving the rise in influenza vaccine demand include the increasing geriatric population, government support, rapid urbanization, rising prevalence of influenza epidemics and seasonal outbreaks, public health awareness, and robust research and development investments. Governments worldwide, in collaboration with international health organizations such as the World Health Organization (WHO), recognize the vital role of influenza vaccination in public health and disease prevention. As a result, they implement various strategies that foster market expansion. They may even subsidize vaccines or offer them free of charge through public health programs, making vaccination more accessible to the general population, leading to the growth of influenza vaccine market. In the coming years, these improvements are expected to significantly enhance healthcare service and stimulate demand for influenza vaccine. The market is expected to grow at a CAGR of approx. 7% during the forecasted period of 2025-2030.

Market Segmentation Analysis:

By Valency: According to the report, the global influenza vaccine market is segmented into two segments based on the valency: Quadrivalent and Trivalent. Quadrivalent segment acquired majority of share in the market in 2024 and is the fastest growing segment as well, as it provides protection against four influenza virus strains (two influenza A strains and two influenza B strains). The demand for quadrivalent vaccines has increased in recent years, driven by factors such as public health recommendations and growing awareness of the seriousness of influenza.

By Vaccine Type: According to the report, the global influenza vaccine market is bifurcated into two types: Inactivated and Live Attenuated. Inactivated segment acquired majority of share in the market in 2024 and is the fastest growing segment as well, as it is made of killed influenza viruses or parts of the viruses and is administrated through injection. The convenience of injection as an administration method and the availability of multiple manufacturers contribute to their widespread use. Furthermore, their well-established safety and effectiveness, public awareness campaigns and pandemic preparedness initiatives are collectively contributing to the growth of inactivated segment in the influenza vaccine market.

By Technology: According to the report, the global influenza vaccine market is bifurcated into two technologies: Egg-based and Cell-based. Egg-based segment acquired majority of share in the market in 2024, due to its long-established infrastructure, proven safety and efficacy, and large-scale production capabilities. Although, cell-based technology is the fastest growing segment as cell culture-based flu vaccine production does not require chicken eggs and has the potential for a faster start-up of the flu vaccine manufacturing process. Even, on August 31, 2016, FDA issued an approval for Seqirus, the sole FDA-approved cell culture-based flu vaccine manufacturer in the United States, to begin using cell culture-grown CVVs.

By Age Group: According to the report, the global influenza vaccine market is bifurcated into two age group: Adults and Pediatrics. Adult segment acquired majority of share in the market in 2024 as the adult population represents a substantial portion of the overall demographic in most regions and adults are more likely to fall into high-risk influenza complications. Furthermore, Adults in the workforce are also crucial targets, not only for their health but also for maintaining economic productivity, prompting employers to encourage vaccination. These factors collectively contribute to adult influenza vaccines maintaining a major market share among age groups in the influenza vaccine market. While, the pediatric segment is expected to register the fastest growing rate during the forecasted period as there is increasing number of influenza virus cases among children and parents are becoming more aware. Even, many countries are implementing school-based influenza vaccination programs to target this age group and reduce influenza transmission in educational settings, leading to growth of this segment.

By Route of Administration: According to the report, the global influenza vaccine market is bifurcated into two routes of administration: Injection and Nasal spray. Injection segment acquired majority of share in the market in 2024 and is the fastest growing segment as well, due to its versatility, proven safety, and broad recommendations. Injections are suitable for diverse populations, spanning infants to seniors and individuals with various health conditions, making them a universal choice. Additionally, injection-based vaccines are widely available and accepted, contributing to their predominant market position and potential for continued growth in the coming years.

By Distribution Channel: According to the report, the global influenza vaccine market is bifurcated into three distribution channels: Hospitals and Pharmacies, Government and Institutions and others. Hospitals and pharmacies hold a major share in the influenza vaccine market in 2024 due to its convenience, and trusted healthcare environments. They serve as go-to locations for receiving influenza vaccines during routine healthcare visits. With their staff of trained healthcare professionals, including nurses and pharmacists, these institutions ensure safe and effective vaccine administration, fostering confidence among vaccine recipients. While, government and institutions are the fastest growing segment during forecasted period due to the ongoing vaccination and immunization programs and the inclusion of influenza vaccines in vaccination programs around the world. For instance, in June 2024, the government of New Zealand expanded access to free-of-cost flu vaccines for children and people with mental health issues.

By Region: The report provides insight into the influenza vaccine market based on the geographical operations, namely North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America influenza vaccine market held the highest market share in 2024, primarily owing to reasons such as increasing prevalence of influenza infection in the US & Canada, increasing public awareness campaigns and educational initiatives, government-sponsored vaccination programs, regulatory support, and the recognition of high-risk groups like the elderly and pregnant women, the region's robust healthcare infrastructure, insurance coverage, and emphasis on patient-centered care. The US is the North America's strongest market for influenza vaccine because of its focus on technological advances in vaccine production, and increasing healthcare expenditure.

Asia Pacific influenza vaccine market is expected to experience fastest growth due to a burgeoning and diverse population, government initiatives and increasing healthcare awareness. Also, the region's vulnerability to seasonal outbreaks, coupled with the memory of past influenza pandemics and COVID pandemic, highlights the importance of vaccination. Furthermore, the availability of health insurance coverage and the growth of international travel further is expected to drive vaccine demand. China holds the largest share in Asia Pacific region owing the growing elderly population, region's vulnerability to seasonal influenza outbreaks and emergence of new flu, nation's expanding healthcare infrastructure, a burgeoning pharmaceutical industry, research and development initiatives, domestic vaccine production and introduction of artificial intelligence in healthcare industry.

Global Influenza vaccine Market Dynamics:

Growth Drivers: Increasing flu Burden among old population has the potential to boost the growth of the influenza vaccine market. As older adults are more vulnerable to influenza, it will significantly contribute to the sales of influenza vaccines. According to CDC, in the US, people 65+ years of age or those with risk factors (e.g., asthma, diabetes, heart disease, immunocompromised) who are infected with the flu are the most likely to experience severe illness or be hospitalized and this could potentially lead to worse outcomes and possible deaths (~85% of flu-related deaths and ~52% of flu-related hospitalizations occur among those 65 and older.). Further, the market is expected to increase due to favorable government initiatives, rapid urbanization, rising prevalence of influenza epidemics and seasonal outbreaks, public health awareness, and robust research and development investments etc.

Challenges: Longer production timeline can present several challenges for the influenza vaccine market. Production timelines for influenza vaccines involve the development, production, and distribution of vaccines for each season. The process takes 5-10 years due to complex clinical development, vaccine research, and regulatory requirements. Regional differences in clinical trials and product approvals from regulatory bodies further complicate the process. Other challenges that influenza vaccine market faces are inequitable access to vaccines and high cost of vaccine development.

Trends: A major trend gaining pace in influenza vaccine market is Artificial Intelligence (AI) and machine learning as it assists in selecting the most appropriate virus strains for vaccines, designing antigens for optimal immune response, and even discovering potential antiviral drugs. Also, AI enables faster and more effective utilization of data collected from genetic testing, clinical trials, and research which reduces vaccine development time and increase efficacy. AI also assists in supply chain management for timely distribution and it monitors influenza spread through data analysis, enabling early outbreak detection. More trends in the market are believed to augment the growth of influenza vaccine market during the forecasted period include, technological advancements in vaccine administration, favorable government initiatives and policies, etc.

Competitive Landscape and Recent Developments:

Global influenza vaccine market is fragmented. Key players of global influenza vaccine market are:

GlaxoSmithKline Plc

Abbott Laboratories

Pfizer Inc.

AstraZeneca Plc

Sanofi S.A.

Moderna Inc.

CSL Limited

Emergent BioSolutions Inc.

Viatris Inc.

BIKEN Co., Ltd.

Serum Institute of India Pvt. Ltd.

Sinovac

GC Biopharma

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their services to emerging markets and more, to maintain a competitive edge in this market. For instance, in June 2024, Sinovac announced a U$100 million investment in Brazil to establish local production of vaccines and monoclonal antibodies, and to advance cell therapy initiatives. While, Moderna's Phase 3 trial of its mRNA-1083 combination vaccine for influenza and COVID-19 met its primary endpoints, showing a stronger immune response than licensed comparators.

Table of Contents

1. Executive Summary

2. Introduction

• 2.1 Influenza Vaccine: An Overview
  • 2.1.1 Common Symptoms of Influenza Virus
• 2.2 Influenza Vaccine Segmentation: An Overview
  • 2.2.1 Influenza Vaccine Segmentation

3. Global Market Analysis

• 3.1 Global Influenza Vaccine Market: An Analysis
  • 3.1.1 Global Influenza Vaccine Market: An Overview
  • 3.1.2 Global Influenza Vaccine Market by Value
  • 3.1.3 Global Influenza Vaccine Market by Valency (Quadrivalent and Trivalent)
  • 3.1.4 Global Influenza Vaccine Market by Vaccine Type (Inactivated and Live Attenuated)
  • 3.1.5 Global Influenza Vaccine Market by Technology (Egg-Based and Cell-Based)
  • 3.1.6 Global Influenza Vaccine Market by Age Group (Adult and Pediatric)
  • 3.1.7 Global Influenza Vaccine Market by Route of Administration (Injection and Nasal Spray)
  • 3.1.8 Global Influenza Vaccine Market by Distribution Channel (Hospitals and Pharmacies, Government and Institutions and Others)
  • 3.1.9 Global Influenza Vaccine Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
• 3.2 Global Influenza Vaccine Market: Valency Analysis
  • 3.2.1 Global Influenza Vaccine Market by Valency: An Overview
  • 3.2.2 Global Quadrivalent Influenza Vaccine Market by Value
  • 3.2.3 Global Trivalent Influenza Vaccine Market by Value
• 3.3 Global Influenza Vaccine Market: Vaccine Type Analysis
  • 3.3.1 Global Influenza Vaccine Market by Vaccine Type: An Overview
  • 3.3.2 Global Inactivated Influenza Vaccine Market by Value
  • 3.3.3 Global Live Attenuated Influenza Vaccine Market by Value
• 3.4 Global Influenza Vaccine Market: Technology Analysis
  • 3.4.1 Global Influenza Vaccine Market by Technology: An Overview
  • 3.4.2 Global Egg Based Influenza Vaccine Market by Value
  • 3.4.3 Global Cell Based Influenza Vaccine Market by Value
• 3.5 Global Influenza Vaccine Market: Age Group Analysis
  • 3.5.1 Global Influenza Vaccine Market by Age Group: An Overview
  • 3.5.2 Global Adult Influenza Vaccine Market by Value
  • 3.5.3 Global Pediatric Influenza Vaccine Market by Value
• 3.6 Global Influenza Vaccine Market: Route of Administration Analysis
  • 3.6.1 Global Influenza Vaccine Market by Route of Administration: An Overview
  • 3.6.2 Global Injectable Influenza Vaccine Market by Value
  • 3.6.3 Global Nasal Spray Influenza Vaccine Market by Value
• 3.7 Global Influenza Vaccine Market: Distribution Channel Analysis
  • 3.7.1 Global Influenza Vaccine Market by Distribution Channel: An Overview
  • 3.7.2 Global Hospitals and Pharmacy Influenza Vaccine Market by Value
  • 3.7.3 Global Government and Institutions Influenza Vaccine Market by Value
  • 3.7.4 Global Others Influenza Vaccine Market by Value

4. Regional Market Analysis

• 4.1 North America Influenza Vaccine Market: An Analysis
  • 4.1.1 North America Influenza Vaccine Market: An Overview
  • 4.1.2 North America Influenza Vaccine Market by Value
  • 4.1.3 North America Influenza Vaccine Market by Region (The US, Canada, Mexico)
  • 4.1.4 The US Influenza Vaccine Market by Value
  • 4.1.5 Canada Influenza Vaccine Market by Value
  • 4.1.6 Mexico Influenza Vaccine Market by Value
• 4.2 Europe Influenza Vaccine Market: An Analysis
  • 4.2.1 Europe Influenza Vaccine Market: An Overview
  • 4.2.2 Europe Influenza Vaccine Market by Value
  • 4.2.3 Europe Influenza Vaccine Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
  • 4.2.4 UK Influenza Vaccine Market by Value
  • 4.2.5 Germany Influenza Vaccine Market by Value
  • 4.2.6 France Influenza Vaccine Market by Value
  • 4.2.7 Italy Influenza Vaccine Market by Value
  • 4.2.8 Spain Influenza Vaccine Market by Value
  • 4.2.9 Rest of Europe Influenza Vaccine Market by Value
• 4.3 Asia Pacific Influenza Vaccine Market: An Analysis
  • 4.3.1 Asia Pacific Influenza Vaccine Market: An Overview
  • 4.3.2 Asia Pacific Influenza Vaccine Market by Value
  • 4.3.3 Asia Pacific Influenza Vaccine Market by Region (China, Japan, India, South Korea and Rest of Asia Pacific)
  • 4.3.4 China Influenza Vaccine Market by Value
  • 4.3.5 Japan Influenza Vaccine Market by Value
  • 4.3.6 India Influenza Vaccine Market by Value
  • 4.3.7 South Korea Influenza Vaccine Market by Value
  • 4.3.8 Rest of Asia Pacific Influenza Vaccine Market by Value
• 4.4 Middle East & Africa Influenza Vaccine Market: An Analysis
  • 4.4.1 Middle East & Africa Influenza Vaccine Market: An Overview
  • 4.4.2 Middle East & Africa Influenza Vaccine Market by Value
• 4.5 Latin America Influenza Vaccine Market: An Analysis
  • 4.5.1 Latin America Influenza Vaccine Market: An Overview
  • 4.5.2 Latin America Influenza Vaccine Market by Value

5. Market Dynamics

• 5.1 Growth Drivers
  • 5.1.1 Increasing Flu Burden Among Adult Population
  • 5.1.2 Rapid Urbanization
  • 5.1.3 Rising Prevalence of Influenza Epidemics And Seasonal Outbreaks
  • 5.1.4 Increased Public Health Awareness
  • 5.1.5 Increasing Government Support
  • 5.1.6 Robust Research and Development Investments
• 5.2 Challenges
  • 5.2.1 Longer Timeline for Vaccine Production
  • 5.2.2 High cost of Vaccine Development
  • 5.2.3 Inequitable Access to Vaccines
• 5.3 Market Trends
  • 5.3.1 Use of AI in Vaccine Development
  • 5.3.2 Technological Advancements in Vaccine Administration
  • 5.3.3 Shift in Trends towards mRNA-based Flu Vaccine

6. Competitive Landscape

• 6.1 Global Influenza Vaccine Players by Market Share
• 6.2 Global Influenza Vaccine Market Players by Vaccines Efficiency and Safety
• 6.3 Global mRNA Influenza Vaccine Market Players by Vaccines in Clinical Development

7. Company Profiles

• 7.1 GlaxoSmithKline Plc
  • 7.1.1 Business Overview
  • 7.1.2 Sales by Products
  • 7.1.3 Business Strategies
• 7.2 Abbott Laboratories
  • 7.2.1 Business Overview
  • 7.2.2 Operating Segments
  • 7.2.3 Business Strategies
• 7.3 Pfizer Inc.
  • 7.3.1 Business Overview
  • 7.3.2 Operating Segments
  • 7.3.3 Business Strategies
• 7.4 AstraZeneca Plc
  • 7.4.1 Business Overview
  • 7.4.2 Operating Regions
  • 7.4.3 Business Strategies
• 7.5 Sanofi S.A.
  • 7.5.1 Business Overview
  • 7.5.2 Operating Segments
  • 7.5.3 Business Strategy
• 7.6 Moderna Inc.
  • 7.6.1 Business Overview
  • 7.6.2 Operating Regions
  • 7.6.3 Business Strategies
• 7.7 CSL Limited
  • 7.7.1 Business Overview
  • 7.7.2 Operating Segments
  • 7.7.3 Business Strategies
• 7.8 Emergent BioSolutions Inc
  • 7.8.1 Business Overview
  • 7.8.2 Operating Segments
  • 7.8.3 Business Strategy
• 7.9 Viatris Inc.
  • 7.9.1 Business Overview
  • 7.9.2 Operating Segments
  • 7.9.3 Business Strategies
• 7.10 BIKEN Co., Ltd.
  • 7.10.1 Business Overview
  • 7.10.2 Business Strategy
• 7.11 Serum Institute of India Pvt. Ltd.
  • 7.11.1 Business Overview
  • 7.11.2 Business Strategy
• 7.12 Sinovac Biotech Ltd.
  • 7.12.1 Business Overview
  • 7.12.2 Business Strategy
• 7.13 GC Biopharma
  • 7.13.1 Business Overview
  • 7.13.2 Business Strategy